gramicidin

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Stem definition	Drug id	CAS RN
naturally occurring antibiotics (undefined group)	4794	1405-97-6

Stem definition

Drug id

CAS RN

naturally occurring antibiotics (undefined group)

4794

1405-97-6

Description:

Molecule	Description
Synonyms: gramicidin gramicidins gramoderm gramicidin D gramicidine gramicidin Dubos	A group of peptide antibiotics from BACILLUS brevis. Gramicidin C or S is a cyclic, ten-amino acid polypeptide and gramicidins A, B, D are linear. Gramicidin is one of the two principal components of TYROTHRICIN. Molecular weight: 9354.60 Formula: C491H701N97O87 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: 548.99 ALOGS: ROTB: None

Molecule

Description

Synonyms:

gramicidin
gramicidins
gramoderm
gramicidin D
gramicidine
gramicidin Dubos

A group of peptide antibiotics from BACILLUS brevis. Gramicidin C or S is a cyclic, ten-amino acid polypeptide and gramicidins A, B, D are linear. Gramicidin is one of the two principal components of TYROTHRICIN.

Molecular weight: 9354.60
Formula: C491H701N97O87
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA: 548.99
ALOGS:
ROTB: None

Date	Agency	Company	Orphan
July 3, 1968	FDA	MONARCH PHARMS

Date

Agency

Company

Orphan

July 3, 1968

FDA

MONARCH PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	353.30	50.40	160	16023	37810	90574454
Anti-cyclic citrullinated peptide antibody	160.42	50.40	84	16099	27137	90585127
Hepatic cirrhosis	156.56	50.40	112	16071	63141	90549123
Joint dislocation	153.72	50.40	97	16086	44485	90567779
Prescribed underdose	152.47	50.40	118	16065	74901	90537363
Hypercholesterolaemia	149.30	50.40	132	16051	100760	90511504
Seronegative arthritis	129.99	50.40	64	16119	18170	90594094
Walking aid user	129.32	50.40	80	16103	35426	90576838
Adjustment disorder with depressed mood	125.73	50.40	94	16089	56659	90555605
Joint stiffness	125.31	50.40	107	16076	77935	90534329
Grip strength decreased	124.90	50.40	115	16068	92461	90519803
Lupus vulgaris	123.62	50.40	85	16098	44974	90567290
Exostosis	115.46	50.40	87	16096	53047	90559217
Disability	114.46	50.40	78	16105	40667	90571597
Bone erosion	113.41	50.40	86	16097	52935	90559329
Wound infection	113.16	50.40	116	16067	106286	90505978
Deep vein thrombosis postoperative	109.44	50.40	95	16088	70714	90541550
Retinitis	108.93	50.40	74	16109	38384	90573880
Lupus-like syndrome	108.40	50.40	81	16102	48765	90563499
Laryngitis	107.84	50.40	82	16101	50671	90561593
Dislocation of vertebra	107.13	50.40	85	16098	55883	90556381
Impaired healing	102.39	50.40	164	16019	234035	90378229
Foot deformity	102.36	50.40	85	16098	59566	90552698
Autoimmune disorder	98.99	50.40	93	16090	76651	90535613
Road traffic accident	96.17	50.40	107	16076	107519	90504745
Sciatica	90.94	50.40	101	16082	101281	90510983
Injury	90.10	50.40	141	16042	197208	90415056
Joint range of motion decreased	88.61	50.40	115	16068	135528	90476736
Hypoaesthesia	86.41	50.40	180	16003	314030	90298234
Type 2 diabetes mellitus	85.63	50.40	140	16043	203104	90409160
Hip arthroplasty	84.49	50.40	85	16098	76123	90536141
Helicobacter infection	82.04	50.40	146	16037	226704	90385560
Osteoporosis	81.17	50.40	93	16090	96438	90515826
Dyspepsia	80.12	50.40	134	16049	198026	90414238
Ear infection	79.51	50.40	79	16104	69696	90542568
Fibromyalgia	76.18	50.40	134	16049	206135	90406129
Amnesia	72.42	50.40	93	16090	108412	90503852
Fall	69.97	50.40	4	16179	481806	90130458
Infusion related reaction	69.66	50.40	197	15986	416583	90195681
Delirium	68.95	50.40	89	16094	104270	90507994
Visual impairment	68.06	50.40	100	16083	132265	90479999
Knee arthroplasty	68.01	50.40	79	16104	83103	90529161
Spondylitis	67.50	50.40	38	16145	14140	90598124
Gait inability	67.30	50.40	105	16078	146351	90465913
Spinal fusion surgery	66.96	50.40	36	16147	12247	90600017
Pulmonary fibrosis	66.87	50.40	89	16094	107414	90504850
Upper respiratory tract infection	66.06	50.40	97	16086	128221	90484043
Chronic sinusitis	65.49	50.40	45	16138	23757	90588507
Irritable bowel syndrome	63.10	50.40	124	16059	207324	90404940
Red blood cell sedimentation rate increased	61.84	50.40	75	16108	82520	90529744
Lower limb fracture	61.71	50.40	76	16107	84937	90527327
Drug-induced liver injury	61.19	50.40	78	16105	90240	90522024
Asthenia	58.66	50.40	12	16171	533739	90078525
Liver function test increased	57.04	50.40	73	16110	84782	90527482
Prescribed overdose	56.42	50.40	78	16105	97547	90514717
Swollen joint count increased	55.69	50.40	83	16100	111123	90501141
Breast cancer stage I	54.69	50.40	29	16154	9595	90602669
Paraesthesia oral	54.05	50.40	45	16138	31614	90580650
Osteoarthritis	53.57	50.40	112	16071	195618	90416646
Folliculitis	51.40	50.40	113	16070	204240	90408024

MedDRA adverse event term

Likelihood ratio

Likelihood ratio threshold

Patients taking drug having adverse event

Patients taking drug not having adverse event

Patients not taking drug having adverse event

Patients not taking drug not having adverse event

Macular degeneration

353.30

50.40

160

16023

37810

90574454

Anti-cyclic citrullinated peptide antibody

160.42

50.40

16099

27137

90585127

Hepatic cirrhosis

156.56

50.40

112

16071

63141

90549123

Joint dislocation

153.72

50.40

16086

44485

90567779

Prescribed underdose

152.47

50.40

118

16065

74901

90537363

Hypercholesterolaemia

149.30

50.40

132

16051

100760

90511504

Seronegative arthritis

129.99

50.40

16119

18170

90594094

Walking aid user

129.32

50.40

16103

35426

90576838

Adjustment disorder with depressed mood

125.73

50.40

16089

56659

90555605

Joint stiffness

125.31

50.40

107

16076

77935

90534329

Grip strength decreased

124.90

50.40

115

16068

92461

90519803

Lupus vulgaris

123.62

50.40

16098

44974

90567290

Exostosis

115.46

50.40

16096

53047

90559217

Disability

114.46

50.40

16105

40667

90571597

Bone erosion

113.41

50.40

16097

52935

90559329

Wound infection

113.16

50.40

116

16067

106286

90505978

Deep vein thrombosis postoperative

109.44

50.40

16088

70714

90541550

Retinitis

108.93

50.40

16109

38384

90573880

Lupus-like syndrome

108.40

50.40

16102

48765

90563499

Laryngitis

107.84

50.40

16101

50671

90561593

Dislocation of vertebra

107.13

50.40

16098

55883

90556381

Impaired healing

102.39

50.40

164

16019

234035

90378229

Foot deformity

102.36

50.40

16098

59566

90552698

Autoimmune disorder

98.99

50.40

16090

76651

90535613

Road traffic accident

96.17

50.40

107

16076

107519

90504745

Sciatica

90.94

50.40

101

16082

101281

90510983

Injury

90.10

50.40

141

16042

197208

90415056

Joint range of motion decreased

88.61

50.40

115

16068

135528

90476736

Hypoaesthesia

86.41

50.40

180

16003

314030

90298234

Type 2 diabetes mellitus

85.63

50.40

140

16043

203104

90409160

Hip arthroplasty

84.49

50.40

16098

76123

90536141

Helicobacter infection

82.04

50.40

146

16037

226704

90385560

Osteoporosis

81.17

50.40

16090

96438

90515826

Dyspepsia

80.12

50.40

134

16049

198026

90414238

Ear infection

79.51

50.40

16104

69696

90542568

Fibromyalgia

76.18

50.40

134

16049

206135

90406129

Amnesia

72.42

50.40

16090

108412

90503852

Fall

69.97

50.40

16179

481806

90130458

Infusion related reaction

69.66

50.40

197

15986

416583

90195681

Delirium

68.95

50.40

16094

104270

90507994

Visual impairment

68.06

50.40

100

16083

132265

90479999

Knee arthroplasty

68.01

50.40

16104

83103

90529161

Spondylitis

67.50

50.40

16145

14140

90598124

Gait inability

67.30

50.40

105

16078

146351

90465913

Spinal fusion surgery

66.96

50.40

16147

12247

90600017

Pulmonary fibrosis

66.87

50.40

16094

107414

90504850

Upper respiratory tract infection

66.06

50.40

16086

128221

90484043

Chronic sinusitis

65.49

50.40

16138

23757

90588507

Irritable bowel syndrome

63.10

50.40

124

16059

207324

90404940

Red blood cell sedimentation rate increased

61.84

50.40

16108

82520

90529744

Lower limb fracture

61.71

50.40

16107

84937

90527327

Drug-induced liver injury

61.19

50.40

16105

90240

90522024

Asthenia

58.66

50.40

16171

533739

90078525

Liver function test increased

57.04

50.40

16110

84782

90527482

Prescribed overdose

56.42

50.40

16105

97547

90514717

Swollen joint count increased

55.69

50.40

16100

111123

90501141

Breast cancer stage I

54.69

50.40

16154

9595

90602669

Paraesthesia oral

54.05

50.40

16138

31614

90580650

Osteoarthritis

53.57

50.40

112

16071

195618

90416646

Folliculitis

51.40

50.40

113

16070

204240

90408024

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	108.76	45.32	44	7183	21615	110560457
Chronic sinusitis	105.83	45.32	45	7182	25039	110557033
Paraesthesia oral	93.14	45.32	45	7182	33626	110548446
Procedural pain	84.91	45.32	43	7184	35522	110546550
Infusion related reaction	83.32	45.32	113	7114	381049	110201023
Sleep disorder due to general medical condition, insomnia type	81.21	45.32	62	7165	105581	110476491
Road traffic accident	73.82	45.32	59	7168	107339	110474733
Vaginal flatulence	72.62	45.32	28	7199	12116	110569956
Vaginal discharge	68.55	45.32	30	7197	17878	110564194
Sciatica	68.32	45.32	53	7174	92346	110489726
Female genital tract fistula	67.57	45.32	29	7198	16490	110565582
Proctitis	63.63	45.32	28	7199	16899	110565173
Frequent bowel movements	61.77	45.32	45	7182	71345	110510727
Dyspepsia	61.69	45.32	69	7158	190896	110391176
Radiculopathy	60.06	45.32	28	7199	19308	110562764
Colitis ulcerative	58.54	45.32	45	7182	77318	110504754
Fibromyalgia	53.90	45.32	61	7166	170848	110411224
Type 2 diabetes mellitus	52.10	45.32	61	7166	177171	110404901
Ill-defined disorder	49.49	45.32	56	7171	156797	110425275
C-reactive protein	48.17	45.32	28	7199	30303	110551769
Impaired healing	45.44	45.32	60	7167	196657	110385415

MedDRA adverse event term

Likelihood ratio

Likelihood ratio threshold

Patients taking drug having adverse event

Patients taking drug not having adverse event

Patients not taking drug having adverse event

Patients not taking drug not having adverse event

Macular degeneration

108.76

45.32

7183

21615

110560457

Chronic sinusitis

105.83

45.32

7182

25039

110557033

Paraesthesia oral

93.14

45.32

7182

33626

110548446

Procedural pain

84.91

45.32

7184

35522

110546550

Infusion related reaction

83.32

45.32

113

7114

381049

110201023

Sleep disorder due to general medical condition, insomnia type

81.21

45.32

7165

105581

110476491

Road traffic accident

73.82

45.32

7168

107339

110474733

Vaginal flatulence

72.62

45.32

7199

12116

110569956

Vaginal discharge

68.55

45.32

7197

17878

110564194

Sciatica

68.32

45.32

7174

92346

110489726

Female genital tract fistula

67.57

45.32

7198

16490

110565582

Proctitis

63.63

45.32

7199

16899

110565173

Frequent bowel movements

61.77

45.32

7182

71345

110510727

Dyspepsia

61.69

45.32

7158

190896

110391176

Radiculopathy

60.06

45.32

7199

19308

110562764

Colitis ulcerative

58.54

45.32

7182

77318

110504754

Fibromyalgia

53.90

45.32

7166

170848

110411224

Type 2 diabetes mellitus

52.10

45.32

7166

177171

110404901

Ill-defined disorder

49.49

45.32

7171

156797

110425275

C-reactive protein

48.17

45.32

7199

30303

110551769

Impaired healing

45.44

45.32

7167

196657

110385415

Source	Code	Description
ATC	R02AB30	RESPIRATORY SYSTEM THROAT PREPARATIONS THROAT PREPARATIONS Antibiotics
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000891	Anti-Infective Agents, Local
MeSH PA	D000900	Anti-Bacterial Agents

Source

Code

Description

ATC

R02AB30

RESPIRATORY SYSTEM
THROAT PREPARATIONS
THROAT PREPARATIONS
Antibiotics

MeSH PA

D000890

Anti-Infective Agents

MeSH PA

D000891

Anti-Infective Agents, Local

MeSH PA

D000900

Anti-Bacterial Agents

Disease	Relation	SNOMED_ID	DOID
Blepharoconjunctivitis	indication	68659002	DOID:2456
Bacterial conjunctivitis	indication	128350005	DOID:9700
Infective blepharitis	indication	312219000
Bacterial keratitis	indication	314557000
Superficial Ocular Infection	indication

Disease

Relation

SNOMED_ID

DOID

Blepharoconjunctivitis

indication

68659002

DOID:2456

Bacterial conjunctivitis

indication

128350005

DOID:9700

Infective blepharitis

indication

312219000

Bacterial keratitis

indication

314557000

Superficial Ocular Infection

indication

Bioactivity Summary:

Target	Class	Pharos	UniProt	Type	Activity value (-log[M])	Bioact source
Thromboxane-A synthase	Enzyme	P24557	THAS_HUMAN	IC50	6.11	DRUG MATRIX
Substance-K receptor	GPCR	P21452	NK2R_HUMAN	Ki	5.82	DRUG MATRIX
Endothelin-1 receptor	GPCR	P25101	EDNRA_HUMAN	Ki	5.74	DRUG MATRIX
Tyrosine-protein kinase Lck	Kinase	P06239	LCK_HUMAN	IC50	5.96	DRUG MATRIX
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN	IC50	5.48	DRUG MATRIX
Melanocortin receptor 4	GPCR	P32245	MC4R_HUMAN	Ki	5.50	DRUG MATRIX
Melanocortin receptor 5	GPCR	P33032	MC5R_HUMAN	Ki	5.72	DRUG MATRIX
Sodium/potassium-transporting ATPase subunit alpha-2	Ion channel		AT1A2_PIG	IC50	5.29	DRUG MATRIX

Target

Class

Pharos

UniProt

Action

Type

Activity value
(-log[M])

Mechanism
action

Bioact source

MoA source

Thromboxane-A synthase

Enzyme

P24557

THAS_HUMAN

IC50

6.11

DRUG MATRIX

Substance-K receptor

GPCR

P21452

NK2R_HUMAN

5.82

DRUG MATRIX

Endothelin-1 receptor

GPCR

P25101

EDNRA_HUMAN

5.74

DRUG MATRIX

Tyrosine-protein kinase Lck

Kinase

P06239

LCK_HUMAN

IC50

5.96

DRUG MATRIX

Tyrosine-protein kinase Fyn

Kinase

P06241

FYN_HUMAN

IC50

5.48

DRUG MATRIX

Melanocortin receptor 4

GPCR

P32245

MC4R_HUMAN

5.50

DRUG MATRIX

Melanocortin receptor 5

GPCR

P33032

MC5R_HUMAN

5.72

DRUG MATRIX

Sodium/potassium-transporting ATPase subunit alpha-2

Ion channel

AT1A2_PIG

IC50

5.29

DRUG MATRIX

External reference:

ID	Source
5IE62321P4	UNII
D04369	KEGG_DRUG
4018774	VUID
N0000147077	NUI
113-73-5	SECONDARY_CAS_RN
4018774	VANDF
C0018165	UMLSCUI
CHEBI:5530	CHEBI
CHEMBL1201469	ChEMBL_ID
DB00027	DRUGBANK_ID
CHEMBL373496	ChEMBL_ID
D006096	MESH_DESCRIPTOR_UI
2025	INN_ID
5011	RXNORM
4800	MMSL
002801	NDDF
004423	NDDF
387524003	SNOMEDCT_US
91479004	SNOMEDCT_US
CHEMBL557217	ChEMBL_ID
3052	INN_ID
73357	PUBCHEM_CID

Source

5IE62321P4

UNII

D04369

KEGG_DRUG

4018774

VUID

N0000147077

NUI

113-73-5

SECONDARY_CAS_RN

4018774

VANDF

C0018165

UMLSCUI

CHEBI

ChEMBL_ID

DRUGBANK_ID

ChEMBL_ID

MESH_DESCRIPTOR_UI

INN_ID

RXNORM

4800

MMSL

002801

NDDF

004423

NDDF

SNOMEDCT_US

SNOMEDCT_US

ChEMBL_ID

INN_ID

PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Neomycin and Polymyxin B Sulfates and Gramicidin	HUMAN PRESCRIPTION DRUG LABEL	3	21695-528	SOLUTION/ DROPS	0.03 mg	OPHTHALMIC	ANDA	19 sections
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN	HUMAN PRESCRIPTION DRUG LABEL	3	24208-790	SOLUTION/ DROPS	0.03 mg	OPHTHALMIC	ANDA	19 sections
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN	HUMAN PRESCRIPTION DRUG LABEL	3	50090-0247	SOLUTION/ DROPS	0.03 mg	OPHTHALMIC	ANDA	18 sections
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN	HUMAN PRESCRIPTION DRUG LABEL	3	54868-6253	SOLUTION/ DROPS	0.03 mg	OPHTHALMIC	ANDA	18 sections
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN	HUMAN PRESCRIPTION DRUG LABEL	3	55045-1194	SOLUTION/ DROPS	0.03 mg	OPHTHALMIC	ANDA	18 sections

Product

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

gramicidin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: